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Abstract The molecular basis for the modulatory properties of
CD99 is not well understood. Treatment of human Jurkat T
lymphocytes with anti-CD99 antibody led to activation of three
mitogen-activated protein kinase (MAPK) members, ERK,
JNK, and p38 MAPK, along with homotypic aggregation. While
phosphorylation of ERK and JNK was inhibited by the
pretreatment of a PKC inhibitor, bisindolylmaleimide I, activa-
tion of p38 MAPK was upregulated by the same pretreatment.
The signaling pathways to MAPKs by CD99 engagement were
independent of PI-3 kinase, distinguishing from those by CD3
engagement. Among MAPKs, ERK pathway was essential for
homotypic aggregation together with intracytoplasmic Ca2+.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
The CD99 protein, a monomeric 32-kDa transmembrane
glycoprotein, has been implicated in various cellular proc-
esses; homotypic aggregation, apoptosis [1,2], vesicular pro-
tein transport [3], and Th1 cell di¡erentiation [4]. The li-
gand(s) for CD99 is not yet known, but ligation of CD99
with anti-CD99 monoclonal antibody (mAb) was shown to
induce a prominent homotypic aggregation of CD4CD8
thymocytes [5] and cell lines such as IM9 B and Jurkat T cells
[6]. So far, signaling pathways taken downstream of CD99 are
poorly understood, although CD99 ligation was shown to
elevate intracellular Ca2 and enhance TCR-dependent cellu-
lar activation [4,7].
In this report, we investigated whether CD99 ligation acti-
vates mitogen-activated protein kinases (MAPKs) in Jurkat T
cells, and which pathway regulates homotypic aggregation.
MAPKs are divided into subfamilies based on speci¢c con-
served residues, particularly a TXY motif in the activation
loop [8]. The well-characterized MAPK subfamilies are the
extracellular signal-related kinase (ERK) subfamily, the c-
jun N-terminal kinase (JNK) subfamily, and p38 MAPK sub-
family. In general, MAPKs of di¡erent subfamilies are acti-
vated by distinct upstream regulators [9], but it seems to be a
rule that redundant pathways are responsible for each MAPK
activation in di¡erent situations. In the case of ERK, this
MAPK is activated strongly by receptor tyrosine kinases or
by T and B cell antigenic receptors which are associated with
non-receptor tyrosine kinases [10,11]. However, ERK was
shown to be activated also by other stimuli including protein
kinase C (PKC) activation, increased intracytoplasmic Ca2,
and heterotrimeric G proteins [12,13]. As well known, ERK is
central to cell growth, supporting the transition from the qui-
escent state to cell cycle [14]. However, the activity of ERK is
found not only in the nucleus but also in the cytoplasm, and it
is thought to be responsible for various cell functions such as
cell di¡erentiation and cytoskeletal rearrangements [15,16]. In
this study, we showed that CD99 triggered all three members
of MAPK subfamily which were regulated di¡erentially. We
also showed that CD99 activated MAPKs independently of
PI-3K and among them, ERK pathway was essential for
CD99-induced homotypic aggregation along with intracyto-
plasmic Ca2.
2. Materials and methods
2.1. Cells and reagents
Jurkat or Jurkat TAg T cells were maintained at 37‡C and 5% CO2
in RPMI 1640 (Gibco, Grand Island, NY, USA), supplemented with
10% fetal calf serum (FCS) (HyClone, Logan, UT, USA), penicillin at
400 units/ml, and streptomycin at 150 Wg/ml. For CD99 ligation, cells
were washed with serum-free RPMI medium or PBS and stimulated
with anti-CD99 (DN16) mAb at 10 Wg/ml and rabbit or goat anti-
mouse IgG at 10 Wg/ml for crosslinking.
Antibodies to phospho-ERK, phospho-JNK, and phospho-p38
were purchased from New England Biolabs (Beverly, MA, USA)
and antibodies against ERK, p38 MAPK and JNK were from Santa
Cruz (Santa Cruz, CA, USA). The mAbs against CD99, DN16 and
YG32, were obtained from DiNonA (Suwon, Korea). Bisindolylma-
leimide I, chelerythrine chloride, SB203580, PD98059, herbimycin A
and 1,2-bis(o-aminophenoxy)ethane-N,N,NP,NP-tetraacetic acid tetra-
(acetoxymethyl) ester (BAPTA-AM) were purchased from Calbio-
chem (La Jolla, CA, USA). Phorbol 12-myristate 13-acetate (PMA)
and wortmannin were from Sigma (St. Louis, MO, USA).
2.2. Cell lysis and immunoblotting
Cells were washed twice in cold PBS and solubilized in lysis bu¡er
(10 mM Tris^HCl, pH 7.6, 150 mM NaCl, 2 mM EDTA, 1% Nonidet
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P-40, 1 mM phenylmethylsulfonyl £uoride (PMSF), 10 Wg/ml aproti-
nin, and 10 Wg/ml leupeptin for 15 min on ice. The lysates were
clari¢ed by centrifugation at 16 000Ug for 15 min at 4‡C, and the
protein concentration was determined using a BCA protein assay kit
(Pierce, Rockford, IL, USA). Immunoblotting of soluble cell lysates
was performed. Brie£y, proteins separated by SDS^polyacrylamide
gels were transferred to PVDF membrane, which was blocked for
60 min in 5% non-fat milk. The membranes were incubated for 60^
120 min in primary antibody, washed three times in TBST, incubated
for 60 min in HRP-conjugated rabbit anti-mouse or goat anti-rabbit
immunoglobulin, and then washed three times. Finally, a chemilumi-
nescence detection system (Amersham, Arlington Heights, IL, USA)
was used for visualization of relevant proteins. Individual blots were
exposed for 30 s to 20 min to gain an optimal signal to noise ratio.
2.3. Cell aggregation assay
Jurkat cells which were growing exponentially in RPMI 1640/10%
FCS were washed twice with RPMI 1640 without serum, adjusted to
106 cells/ml, and 100 Wl (1U105 cells) were placed into wells of £at-
bottom 96-well tissue-culture plates (Corning, Corning, NY, USA).
Cells were stimulated with 1 Wg/ml anti-CD99 mAb (DN16 or YG32).
The primary antibodies were crosslinked by adding goat anti-mouse
IgG (1 Wg/ml). 100 Wl of serum-free RPMI 1640 was added to the
wells and the contents of the wells were mixed by gentle pipetting.
Plates were incubated for 3^4 h at 37‡C before photographing the
wells or determination of the degree of aggregation. Semiquantitative
scoring of the index of adhesion was carried out as described [6].
3. Results
3.1. Phosphorylation of three di¡erent MAPK family members,
ERK, JNK, and p38 MAPK following CD99 crosslinking
To understand how engagement of CD99 triggers various
kinds of modulatory e¡ects, we ¢rst tested whether CD99
crosslinking in Jurkat T cells induces activation of members
of the MAPK family; ERK, JNK, and p38 MAPK. Cell
lysates were prepared from Jurkat T cells stimulated with
anti-CD99 (DN16) mAb and second crosslinking antibody
for given durations. As an assay for MAPK activation, we
measured the phosphorylation of MAPKs by immunoblotting
using antibodies against ERK and phospho-ERK; JNK and
phospho-JNK; and p38 MAPK and phospho-p38 MAPK.
Both phosphorylated ERK1 and ERK2 were detected be-
tween 5 and 15 min after anti-CD99 stimulation (Fig. 1A).
Phosphorylation of JNK and p38 MAPK was also evident at
5 min (Fig. 1B,C). Maximal phosphorylation of ERK1,
ERK2, JNK and p38 MAPK was reached between 10 and
30 min after CD99 engagement. ERK activation appeared
to be much stronger than those of JNK and p38 MAPK.
3.2. CD99-induced activation of ERK and JNK, but not of
p38 MAPK, requires PKC activity
Next we addressed if all three MAPKs were activated in a
similar manner or di¡erentially regulated. We utilized several
Fig. 1. Phosphorylation of MAPKs by CD99 ligation. Jurkat T cells
were stimulated with anti-CD99 mAb or PMA. After indicated
time, cell lysates were immunoblotted by anti-phospho-ERK and
anti-ERK antibody (A); anti-phospho-JNK and anti-JNK (B); and
anti-phospho-p38 MAPK and anti-p38 MAPK (C).
Fig. 2. E¡ect of chemical inhibitors on CD99-induced MAPK phosphorylation. A: Jurkat T cells were stimulated with anti-CD99 mAb 1 h
after pretreatment of chemical inhibitors as shown (B, bisindolylmaleimide I 10 WM; C, chelerythrine chloride 4 WM; H, herbimycin A 2 WM;
W, wortmannin 100 nM). Duration of stimulation with anti-CD99 mAb was given in minutes. All experiments with chemical inhibitors and
PMA were done with stimulation for 30 min. As a positive control, Jurkat cells were stimulated with 50 nM PMA for 30 min with or without
pretreatment of bisindolylmaleimide I (right two lanes). Cell lysates were immunoblotted by anti-phospho-ERK (upper panel), anti-ERK anti-
body (middle panel) and anti-phospho-p38 MAPK (lower panel). B: Lysates from Jurkat cells stimulated with anti-CD99 mAb in the absence
or presence of given chemical inhibitors were immunoblotted by anti-phospho-JNK (upper panel), anti-JNK antibody (lower panel). C: The rel-
ative intensity of MAPK (ERK, JNK, and p38 MAPK) phosphorylation. The extent of MAPK phosphorylation obtained from anti-CD99
stimulation in the absence of any inhibitors was arbitrarily shown as 100. The relative intensity of the bands was determined by NIH image.
For each analysis, the extent of MAPK phosphorylation was corrected by the intensity of total MAPK level.
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inhibitors to test whether they block CD99-mediated MAPK
activation. The requirement of PKC and PI3-K for CD99-
mediated activation of MAPKs was investigated by bisindo-
lylmaleimide I, a speci¢c inhibitor of PKC, and wortmannin,
a PI3-K inhibitor, respectively. As shown in Fig. 2A, the
pretreatment of Jurkat cells with bisindolylmaleimide I re-
sulted in a substantial blockade of CD99-mediated activation
of ERK. However, ERK phosphorylation was slightly inhib-
ited by chelerythrine chloride or herbimycin and was not
blocked by wortmannin. These results suggest that ERK acti-
vation is dependent on the PKC activity. JNK phosphory-
lation was also a similar case to ERK phosphorylation (Fig.
2B). JNK activity was greatly inhibited by bisindolylmale-
imide I and only very slightly by wortmannin. Therefore,
ERK and JNK appeared to be activated downstream of
some forms of bisindolylmaleimide I-inhibitable PKC.
In contrast to ERK and JNK, p38 MAPK phosphorylation
was not inhibited, but enhanced by the pretreatment of bisin-
dolylmaleimide I (Fig. 2A), suggesting that p38 MAPK is
regulated independently of ERK or JNK. The relative phos-
phorylation of MAPKs was summarized in Fig. 2C, by adjust-
ing so that the level of MAPK phosphorylation is 100 when
cells were stimulated with anti-CD99 mAb in the absence of
any inhibitor. The di¡erential regulation of of ERK and p38
MAPK was further revealed by the dependence on intracyto-
plasmic Ca2. Based on the report that CD99 engagement
elevates intracytoplasmic Ca2 [4], we tested whether activa-
tion of ERK and p38 MAPK was inhibited by a intracyto-
plasmic Ca2 inhibitor, BAPTA-AM. As shown in Fig. 3,
ERK phosphorylation was downregulated with the pretreat-
ment of a high concentration (60 WM) of BAPTA-AM, but
p38 phosphorylation was enhanced by the same treatment.
Therefore, we showed that ERK, JNK, and p38 MAPK
were di¡erentially regulated based on the di¡erence in PKC
and intracytoplasmic Ca2 dependency. It appeared that
phosphorylation of ERK and JNK was inversely correlated
with that of p38 MAPK in some situations such as PKC or
Ca2 inhibition, although all MAPKs are activated by CD99
engagement.
3.3. CD3 engagement activates all three MAPK members,
but in a di¡erent manner
Since CD99 was recently reported to be a costimulatory
molecule which lowers the requirement of the extent of
Fig. 3. E¡ect of BAPTA-AM on CD99-induced phosphorylation of
ERK and p38 MAPK. Jurkat T cells were stimulated for 30 min
with anti-CD99 mAb 1 h after pretreatment of BAPTA-AM at giv-
en ¢nal concentrations as indicated. Cell lysates were immunoblot-
ted by anti-phospho-ERK (upper panel), anti-ERK antibody (mid-
dle panel) and anti-phospho-p38 MAPK (lower panel).
Fig. 4. E¡ect of chemical inhibitors on CD3-induced MAPK phos-
phorylation. Jurkat T cells were stimulated with OKT3 anti-CD3
mAb 1 h after pretreatment of chemical inhibitors as shown (B, bis-
indolylmaleimide I 10 WM; C, chelerythrine chloride 4 WM; H, her-
bimycin A 2 WM; W, wortmannin 100 nM). Duration of stimula-
tion with anti-CD3 was given in minutes. All experiments with
chemical inhibitors were done with stimulation for 15 min. Cell ly-
sates were immunoblotted by antibodies as indicated.
Fig. 5. E¡ect of chemical inhibitors on CD99-induced homotypic
aggregation. Jurkat T cells were stimulated in the absence of serum
with DN16 anti-CD99 mAb 1 h after pretreatment of various chem-
ical inhibitors. Photography taken at 2 h after CD99 engagement or
control treatment. A: left panel; no stimulation, middle panel;
CD99 engagement, right panel; CD99 engagement after the pre-
treatment of PD98059. Aggregation score was measured according
to the previously described criteria in B. CD99 engagement was per-
formed 1 h after the pretreatment of given chemical inhibitors. (N,
no treatment; Wor, wortmannin 100 nM; BIM, bisindolylmaleimide
I 10 WM; PD, PD98059 50 WM; SB, SB203580 10 WM; PD+SB,
combined treatment of PD98059 50 WM and SB203580 10 WM; BA,
BAPTA-AM 30 WM).
FEBS 23469 23-3-00
M.-J. Hahn et al./FEBS Letters 470 (2000) 350^354352
TCR stimulation which is well known to activate MAPKs
[7,17^20], we compared the signaling requirements for
MAPK activation by CD99 ligation to those of CD3 engage-
ment. As shown in Fig. 4, ligation of CD3 led to activation of
all three MAPKs; ERK, JNK, and p38 MAPK. However, the
signaling requirements for MAPKs were di¡erent from those
of CD99 engagement. ERK phosphorylation was not inhib-
ited by bisindolylmaleimide I or wortmannin, but JNK phos-
phorylation was inhibited by either bisindolylmaleimide I or
wortmannin. These results indicate that the signaling pathway
leading to the activation of ERK and JNK by CD3 is com-
posed of at least two components; PKC-dependent and PI3-
K-dependent ones. In the case of p38 MAPK, the activation
of p38 MAPK by CD3 was not blocked by bisindolylmale-
imide I, but slightly inhibited by wortmannin. With these
results, we could interpret that CD3 and CD99 utilize di¡er-
ent signaling pathways to activate ERK and JNK.
3.4. CD99-induced homotypic aggregation is dependent on
MAPK kinase (MEK) and calcium, but not on PKC
To investigate the signaling pathway for CD99-induced ho-
motypic aggregation, we tested if pharmacological signaling
inhibitors blocked CD99-induced homotypic aggregation in
Jurkat and Molt-4 T cells. Wortmannin for PI3-K, PD98059
for MEK-1, SB203580 for p38 MAPK, BAPTA-AM for in-
tracellular Ca2, and bisindolylmaleimide I for PKC were
used in the indicated concentrations. In both cell lines, the
treatment with e¡ective concentration of wortmannin or bis-
indolylmaleimide I did not inhibit homotypic aggregation at
all and SB203580 inhibited homotypic aggregation only very
slightly. In contrast, BAPTA-AM and PD98059 blocked ho-
motypic aggregation signi¢cantly (Fig. 5). These data indi-
cated that the signaling pathway leading to homotypic aggre-
gation is largely dependent on MEK-1/ERK pathway and
intracytoplasmic Ca2.
4. Discussion
The function of CD99 began to be elucidated recently and
its role in pathogenesis in Hodgkin’s disease was suggested
[21]. It is likely that CD99 plays a role in the maintenance
of cell shape and cell division. So far, the natural ligand for
CD99 is unknown, but it appeared that CD99 has a certain
function operating perpetually in in vitro cultured cells since
its ablation by anti-sense CD99 construct produced a distinct
phenotype as reported [21]. It could be speculated that the
ligand for CD99 may be present in the usual culture condi-
tion; contained in serum, secreted by cells, or expressed on the
cell surface. Fortunately, antibodies against CD99 act as a
strong agonist for CD99 and stimulate intracellular signaling
events. In this study, DN16 and YG32 anti-CD99 antibodies
were used for elucidation of the signaling pathways activated
by CD99 ligation. The e¡ect was not clearly Fc receptor-medi-
ated since isotype-matched control antibody did not activate
the signaling pathways induced by anti-CD99 antibody.
In this study, we paid attention to homotypic aggregation
along with activation of MAPKs. In lymphocytes, LFA-1, a
heterodimer of integrins KL and L2, has a crucial role in
intercellular adhesion and was shown to be also essential in
CD99-induced homotypic aggregation [6]. Signalling pathway
leading to LFA-1 activation or signaling from LFA-1 are well
described [22,23]. Many signaling and cytoskeletal molecules
are shown to interact with the cytoplasmic domains of LFA-1,
which include ILK, FAK, K actinin, talin, RACK-1, and so
on. It is thought that most of them are players of post-recep-
tor events while some of them are involved in the induction of
high avidity state of LFA-1. Cytohesin was implicated in the
pathway for conversion of LFA-1 from low avidity to high
avidity status and was shown to be downstream of phospha-
tidylinositol-3 kinase [24,25]. PI 3-kinase was implicated in
integrin-mediated adhesion triggered by various kinds of
stimuli [26]. On the other hand, PKC plays a crucial role in
homotypic aggregation in some occasions. Phorbol esters
were reported to cause formation of LFA-1/ICAM-1-depen-
dent cell aggregation in some types of cells although it did
not in Jurkat T cells in our laboratory [27]. It appeared that
PI 3-kinase and PKC are responsible for a⁄nity change of
LFA-1 and post-receptor events, respectively. In this study,
we showed that homotypic aggregation induced by CD99
was independent of both PI 3-kinase and PKC. Therefore, it
appeared that CD99 induced homotypic aggregation in a sig-
naling pathway which is di¡erent from the ways described
above.
The homotypic aggregation triggered by CD99 ligation was
shown to be dependent on MEK-1 and Ca2. We performed
homotypic aggregation assays repeatedly and found that some
sorts of serum factors supplemented the requirement for
MEK since the homotypic aggregation was not inhibited by
PD098059 in the presence of serum, but it was still blocked by
the addition of BAPTA-AM, implicating the absolute require-
ment of Ca2 (data not shown). Our data presented here were
obtained in the absence of serum to exclude these complicat-
ing factors in serum. With respect to PKC, we also obtained
some con£icting data in that the inhibition of PKC by bisin-
dolylmaleimide I blocked ERK activation, but not homotypic
aggregation. We think that the elucidation of the exact PKC
isoforms which is activated by CD99 ligation is mandatory to
resolve this dilemma. It is one of several possible explanations
that the residual activity of ERK in the presence of bisindo-
lylmaleimide I could be due to some fractions or subtype(s) of
PKC which could not be inhibited by bisindolylmaleimide I
and this residual ERK activity was su⁄cient to induce homo-
typic aggregation. It is also possible that some isoforms of
PKC promote homotypic aggregation, but other isoforms in-
hibit aggregation and bisindolylmaleimide I operated in an
overall direction so that it blocked PKCs which inhibited
homotypic aggregation. The study exploiting the PKC iso-
form will be needed to understand the exact signaling path-
way downstream of CD99.
In this report, we showed that three di¡erent MAPKs were
activated in response to CD99 ligation. We do not know
whether CD99 elicits all these MAPKs in physiologic situa-
tions or activates only some of them depending on environ-
mental and cellular conditions. Although anti-CD99 antibody
may give a very strong stimulus which is not achieved in the
physiological conditions, it is thought to be signi¢cant to note
that CD99 was capable of eliciting activation of these
MAPKs. Among these, ERK appeared to be the principal
MAPK and MEK-1 which is upstream of ERK was essential
for homotypic aggregation along with Ca2.
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